KLOW Blend protocol

Standard

Week 1

10u

1 mg · Daily

Loading. 1 mg GHK-Cu + 0.2 mg each of BPC/TB/KPV per dose.

Week 2

15u

1.5 mg · Daily

Ramp. 1.5 mg GHK-Cu + 0.3 mg each of BPC/TB/KPV per dose.

Weeks 3–8

20u

2 mg · Daily

Working dose. 2 mg GHK-Cu + 0.4 mg each of BPC/TB/KPV per dose.

Aggressive

30–40u

3–4 mg · Daily (AM + PM split)

Bump here ONLY if 2+ weeks at 2 mg with zero injection-site issues AND a specific high-demand goal. Start at 3 mg (= 0.6 mg each of BPC/TB/KPV). Push to 4 mg only if 3 mg is producing visible results and you want to test further, no published benefit above 3 mg/day; cost roughly doubles.

Off

4 weeks

Mandatory copper-accumulation washout. Do not skip, especially after an Aggressive phase.

Phase	How often	Dose	Units	Notes
Week 1	Daily	1 mg	10u	Loading. 1 mg GHK-Cu + 0.2 mg each of BPC/TB/KPV per dose.
Week 2	Daily	1.5 mg	15u	Ramp. 1.5 mg GHK-Cu + 0.3 mg each of BPC/TB/KPV per dose.
Weeks 3–8	Daily	2 mg	20u	Working dose. 2 mg GHK-Cu + 0.4 mg each of BPC/TB/KPV per dose.
Aggressive	Daily (AM + PM split)	3–4 mg	30–40u	Bump here ONLY if 2+ weeks at 2 mg with zero injection-site issues AND a specific high-demand goal. Start at 3 mg (= 0.6 mg each of BPC/TB/KPV). Push to 4 mg only if 3 mg is producing visible results and you want to test further, no published benefit above 3 mg/day; cost roughly doubles.
Off	4 weeks	–	–	Mandatory copper-accumulation washout. Do not skip, especially after an Aggressive phase.

Cycle & timing

Cycle: 8 weeks on / 4 weeks off, matches GHK-Cu copper-accumulation limits.

Timing: Daily SubQ, anytime; same as GLOW base.

Where: SubQ near target tissue. Rotate.

What to expect

Broader anti-inflammatory coverage than GLOW, preferred for IBD, Crohn’s, joint inflammation, and post-surgical recovery. KPV adds gut/inflammatory coverage. 8-week cycle, 4-week washout.

How much to buy

For 8-wk @ 2 mg × 7/wk; reconstituted shelf life ~28 days.:

3

× 80mg vials

Men & women

Unisex (GHK-Cu + BPC-157 + TB-500 + KPV), same protocol for men and women, no cycle effect. Avoid in pregnancy.

Recommended mixes

Vial	Water	Strength
80 mg	5 mL	GHK-Cu 10 mg/mL; BPC-157 2 mg/mL; TB-500 2 mg/mL; KPV 2 mg/mL

80 mg: 1 unit = 0.10 mg

Storage

PowderFreeze-dried: -4°F.
MixedReconstituted: 36–46°F, protected from light, use within ~28 days (rate-limited by GHK-Cu component).

Don't use if: Active malignancy (TB-500 angiogenesis; BPC-157 tissue growth) · Wilson’s disease, copper dysregulation, copper allergy (GHK-Cu component) · Alpha-MSH allergy (KPV is an alpha-MSH C-terminal fragment) · Active bleeding or recent hemorrhagic stroke (TB-500 vascular effects) · Pregnancy, lactation

Stop if you notice

New mass or unexpected tissue growth at any injection site
Skin discoloration or neurological symptoms (copper toxicity)
New skin pigmentation changes (KPV alpha-MSH activity)
Persistent injection-site reactions beyond 7 days

Side effects

Usually minimal.

Drug interactions

NSAIDs: don’t blunt the blend (a myth); skip during a repair cycle, NSAIDs slow healing themselves; High-dose vitamin C same session: theoretical copper redox interaction (GHK-Cu); Anticoagulants: caution with TB-500 vascular effects; Other alpha-MSH agonists (Melanotan I/II): theoretical receptor overlap with KPV

Labs

Compound-specific: hsCRP (baseline + end); Serum copper and ceruloplasmin if cycles extend beyond 6 weeks; Out of range? Rising serum copper = it’s accumulating → re-dose lower.

What these labs mean →

Warnings

Four-compound blend with no human RCT data on the combination. GHK-Cu: copper accumulation risk with extended cycling, 4–6 week off period is mandatory. BPC-157: FDA Category 2 in 2023; compounding restricted. TB-500: theoretical malignancy concern via angiogenesis; no published human trials. KPV: limited human data; use for gut indications is community-standard but not RCT-supported. BPC-157, TB-500 & KPV were all RECOMMENDED for the 503A bulks list by PCAC (8–6 each, Jul 2026; advisory, non-binding).

Patient education

Four-peptide blend: any single-component contraindication applies to the whole blend. Continuous use without washout risks copper accumulation. Inject SubQ near target tissue. Rotate sites to reduce GHK-Cu sting.

These apply on top of the universal safety rules.

Pairs well with

CJC-1295 No DAC + Ipamorelin

systemic GH + local repair

CJC-1295 (No DAC) + Ipamorelin

Thymosin Alpha-1

immune amplification

Thymosin Alpha-1

Avoid with

NSAIDs during a repair cycle

ibuprofen/Advil/Aleve slow healing on their own; use Tylenol for pain

High-dose vitamin C same session

copper oxidation

Can KLOW Blend + CJC-1295 (No DAC) + Ipamorelin share a syringe?

Can share a syringe. Both are water-based. Combine them if you dose on the same schedule and site.

Changes from the guide

The guide contradicted itself or had a slip here, so this page differs from the PDF:

Patient education also gave a different cycle (Cycle discipline: 4–6 weeks on / 4–6 weeks off). Removed so the page uses the main cycle line: 8 weeks on / 4 weeks off, matches GHK-Cu copper-accumulation limits.
Storage said 6 weeks once mixed; the supply math said ~28 days. Uses the shorter 28 days.
The guide said 2 × 80 mg vials; the 8-week ramp needs 3.

What it does

Four-peptide blend, and angiogenesis. KPV adds MC1R/MC3R anti-inflammation for gut, joints, and skin.

References

researchdosing peptidedosages PubMed thepeptidereport peptides.id

From the guide, page 50.